Evidence map›Paper›PMID 40478325›Full record

ArticleAging clinical and experimental research2025

Eye movement parameters as biomarkers for diagnosis and levodopa responsiveness in patients with Parkinson's disease.

Qibing Luo, Ziqi Gao, Qi Qi, Siming Rong, Rui Yang, Chentao He, Mengfei Cai, Piao Zhang, Yuhu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qibing LuoGuangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, 510080, China.
Ziqi GaoDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Qi QiDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Siming RongDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Rui YangDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Chentao HeDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Mengfei CaiDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Piao ZhangDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan Er Road, Guangdong Province, Guangzhou, 510080, China.
Yuhu ZhangGuangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, 510080, China. zhangyuhu@gdph.org.cn.

Funding

China Postdoctoral Science Foundation 2023M730742Key Technologies Research and Development Program of Guangzhou Municipality 202206010086National Natural Science Foundation of China 82071419National Natural Science Foundation of China 82301663
6 · The paper itself

Abstract

backgroundAbnormalities in characteristic eye movements have been identified in Parkinson's disease (PD) patients.

aimTo determine if eye movement parameters can serve as biomarkers for diagnosing PD and predicting therapeutic responses to levodopa.

methodsWe enrolled 128 PD patients and 28 healthy controls, assessing eye movements before and after levodopa administration.

resultsSpecific eye movement parameters robustly differentiated PD patients from controls, with an AUC of 0.856, and maintained robustness post-levodopa. Correlations were found between changes in eye movement parameters and motor symptom improvements, leading to a predictive model for levodopa responsiveness with an AUC of 0.783. DISCUSSION AND

conclusionsEye movement assessments offer an objective tool for PD diagnosis and levodopa responsiveness prediction.

Indexed as

Antiparkinson AgentsEye MovementsLevodopaParkinson DiseaseAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedAntiparkinson AgentsBiomarkersLevodopaAntisaccadeBiomarkersLevodopaParkinson’s diseaseProsaccades

Identifiers

PMID40478325
PMCPMC12144069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.